From January 1, 2022, the new version of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue was officially implemented. In addition to the "700,000 one-shot" sky-high price rare disease drug price reduction caused by the brush screen, the public's attention to tumor drugs has also been reduced again, bringing the gospel to cancer patients.
After the adjustment of the national medical insurance drug list in 2021, 74 new drugs were added, involving 21 clinical groups. In addition to 7 kinds of drugs for rare diseases, it also includes 18 kinds of tumor drugs, 20 kinds of chronic disease drugs, 15 kinds of anti-infective drugs, as well as 2 kinds of new crown pneumonia treatment drugs, 12 kinds of drugs in other fields, and patients benefit a wide range. In this national medical insurance negotiation, domestic innovative drugs have become a well-deserved protagonist data. The data shows that the average price of 67 exclusive drugs successfully negotiated by the national medical insurance is 61.71%, and the price reduction rate hit a record high. Among them, 66 were the drugs listed last year, and the inclusion of new drugs reached 99%.
Nanfang + reporter learned from BeiGene that the three new indications of PD-1 monoclonal antibody Bai Zean (terelizumab injection) independently developed by BeiGene were all included in medical insurance, covering lung cancer and liver cancer patients.
With the implementation of the new version of the medical insurance catalogue, Bai Zean has relapsed and refractory classical Hodgkin lymphoma, urinary urothelial carcinoma with platinum-containing chemotherapy failure, non-resectable late and advanced lung squamous cell carcinoma first line, non-surgically resectable late and advanced drive gene wild type non-squamolo cell carcinoma line, at least one systemic treatment of hepatocellular carcinoma five indications have been included in medical insurance, becoming the current listed anti-PD-1/L1 antibody has the most indications included in medical insurance.
It is reported that the new price before the reimbursement of Bai Zean Medical Insurance was adjusted to 1450 yuan / bottle (100mg), the price dropped by 33.49%, and the annual treatment cost was less than 50,000 yuan. According to the 80% reimbursement ratio of medical insurance (based on the actual reimbursement ratio of each place), the annual treatment cost paid by patients is only less than 10,000 yuan. The adjustment of the national medical insurance catalogue has led to profound changes in the use of drugs, further expanded the beneficiary population, greatly improved the accessibility and fairness of drugs, and once again demonstrated the innovation, advancement and purpose of China's medical insurance system.
The three new indications of Bai Zean include the first line of late and advanced lung squamous cell carcinoma that cannot be inoperated, the first line of non-squamous cell carcinoma of the wild type of late and advanced driving genes that cannot be inoperated, and hepatocellular carcinoma that has undergone at least one systemic treatment. Bai Zean has also become the only PD-1 monoclonal antibody in the field of liver cancer that is not reimbursed by the treatment plan. BeiGene revealed that with the implementation of the new version of the medical insurance catalogue, Bai Zean has become the only immunotherapy drug covered by medical insurance that cannot be surgically removed for locally advanced or advanced NSCLC lung squamous cell carcinoma combined with the yew protocol, further reducing the burden on patients.
The price of anti-cancer drugs has dropped again and again, can the production capacity be guaranteed? It is reported that the current production and supply of Bai Zean is jointly provided by the German Boehringer Ingelheim Biopharmaceutical Industry with a century-old history and the BeiGene Guangzhou Biopharmaceutical Industry Base. The first and second phases of the BeiGene production base have been completed in September 2019 and December 2020 respectively, and the biological agent production facility with a production capacity of 24,000 liters has been built, and the planned production capacity of the third phase of the plant is 40,000 liters, and the construction is expected to be completed by the end of 2022, and the total production capacity will reach 64,000 liters after completion, which further enhances the market supply capacity and provides a strong guarantee for the accessibility of drugs.
[Reporter] Yan Huifang
【Author】 Yan Huifang
Healthy living circle
![200 billion giant pharmaceutical companies were born! Unfortunately, the first day caught up with the big fall[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)